News
IBIO
4.060
+20.83%
0.700
12 Health Care Stocks Moving In Friday's Pre-Market Session
Avalo Therapeutics stock rose 289.1% to $18.48 during Friday's pre-market session. Xilio Therapeutic (XLO) shares moved upwards by 205.16% during the session. Biodexa Pharmaceuticals (BDRX) shares also moved upwards. Losers NuCana (NCNA) and Yield10 Bioscience (YTEN) fell in the pre- market session.
Benzinga · 2h ago
iBio, Mesoblast, Kodiak Sciences among healthcare movers
IBio, Mesoblast, Kodiak Sciences among healthcare movers. S&P 500 Health Care Sector +0.18% to 1725.9. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. S&p 500 Healthcare Equipment & Services among healthcare mover.
Seeking Alpha · 1d ago
SMR, GCTS and GSIW among mid-day movers
On the Move SMR, GCTS and GSIW among mid-day movers. GCT Semiconductor Holding (GCTS) and iBio are among the biggest gainers in the SA market. SMR and GCSR among the largest losers.
Seeking Alpha · 1d ago
iBio climbs after AI-led drug discovery deal
IBio, Inc. Shares more than doubled on Thursday. The biotech announced a collaboration with privately held AstralBio to develop drugs for obesity and other cardiometabolic conditions. IBIO will leverage its AI/machine learning platform to develop the drugs. The deal is funded by a $15M private placement.
Seeking Alpha · 1d ago
Canada Goose Layoffs 2024: What to Know About the Latest GOOS Job Cuts
Canada Goose stock is up 5% as of Wednesday morning. The luxury clothing company announced job cuts for its corporate headquarters. The layoffs are part of the company's Transformation Plan. Rent the Runway stock, iBio shares and Xpeng stock are all up on Wednesday.
Investorplace · 1d ago
RENT Stock Alert: Rent the Runway Preps for a 1-for-20 Reverse Stock Split
Rent the Runway stock will undergo a one-for-20 reverse stock split on April 2. The designer closet company is going to consolidate 20 shares of RENT stock into a single share. The company is enacting the reverse split to increase the price of its shares. IBio, Xpeng and Hannover Rueck stock are all moving Wednesday.
Investorplace · 2d ago
iBio Shares Double After Collaboration Agreement With AstralBio
IBio shares doubled after the company entered into a collaboration agreement with AstralBio to develop novel antibodies to treat obesity and other cardiometabolic conditions. IBio closed a $15 million private placement financing on Tuesday. The stock hit its 52-week low of $1.02 and is down 95% in the past year.
Dow Jones · 2d ago
Why Is iBio (IBIO) Stock Up 125% Today?
IBio is partnering with AstralBio to develop “novel antibodies.” The antibodies may eventually become treatments for cardiometabolic diseases, including obesity. IBio raised $15 million in a private placement yesterday. The company generated no revenue in its last fiscal year.
Investorplace · 2d ago
Micro-Cap Stock iBio Doubles On Wednesday - Here's Why
IBio Inc (NYSE:IBIO) shares are surging after the company entered into a collaboration agreement with AstralBio Inc. To develop antibodies to treat obesity and other cardiometabolic conditions. The shares are trading over 100% with a strong session volume of 38.98 million. This micro-cap biotech player is valued at $4 million, with an enterprise value of $17.7 million.
Benzinga · 2d ago
iBio, ImmunityBio, Mesoblast among healthcare movers
IBio, ImmunityBio, Mesoblast among healthcare movers. S&P 500 Health Care Sector +1.04% to 1717.5. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index. IBio, immunityBio, mesoblast are among the biggest gainers.
Seeking Alpha · 2d ago
Market-Moving News for March 27th
IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases. Direct Digital Holdings shares are lower after reporting worse-than-expected Q4 financial results. Novocure shares are higher after company's lung cancer trial met primary endpoint.
Benzinga · 2d ago
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
IBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets. The company has entered into a collaboration agreement with AstralBio, Inc. To develop novel antibodies to treat obesity and other cardiometabolic conditions. IBio announced a $15 million private placement financing yesterday.
Forward News · 2d ago
iBio announces $15 million private placement
IBio, Inc. Announces $15 million private placement. The company intends to use the net proceeds from the offering for general corporate purposes. IBio expects the proceeds to fund its operating plan through fiscal year 2025. The fully subscribed PIPE financing included participation from institutional and accredited investors.
Seeking Alpha · 2d ago
Reported Earlier, iBio Raises $15M In Equity Financing, Shares Set At $2.85 Each
IBio, Inc. Is an AI-driven innovator of precision antibody immunotherapies. The company has entered into a securities purchase agreement for a private investment in public equity financing. The financing is expected to result in gross proceeds of approximately $15.0 million.
Benzinga · 2d ago
*IBio Announces $15M Private Placement
Dow Jones · 2d ago
Press Release: iBio Announces $15.0 Million Private Placement
IBio Announces $15.0 million Private Placement -- Purchase price of $2.85 represents a premium of 148+% to last close. The Company intends to use the net proceeds from the offering for general corporate purposes. IBio is an AI-driven innovator of precision antibody immunotherapies.
Dow Jones · 2d ago
Weekly Report: what happened at IBIO last week (0318-0322)?
Weekly Report · 4d ago
12 Best Biotech Penny Stocks to Invest In
Acasti Pharma Inc. (NASDAQ:ACST) is one of the best biotech penny stocks to invest in. The biotech sector is expected to bounce back to pre-pandemic levels of growth in 2024. The performance of biotech giants like GlaxoSmithKline plc and Eli Lilly and Company shows increased optimism in the sector.
Forward News · 4d ago
Weekly Report: what happened at IBIO last week (0311-0315)?
Weekly Report · 03/18 09:41
Weekly Report: what happened at IBIO last week (0304-0308)?
Weekly Report · 03/11 09:40
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, CCR8 and PD-1 Agonist. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.